Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
03 aug 2012 - 07:56
Statutaire naam
Galapagos NV
Titel
Galapagos delivers solid half year results 2012
Bericht
Patients for GLPG0634 Phase 2a study now fully recruited
• Group revenues €64.5 M compared to €39.7 M in H1 2011 (+62%)
• Group net loss €11.3 M compared to €27.7 M loss last year
• Cash position of €122.6 M on 30 June 2012
• Service division external revenues €32.9 M compared to €24 M last year (+37%)
• Services EBITDA €5.7 M compared to €3.7 M last year (+54%)
• Full year guidance reiterated: €150 M in revenues, positive operating result and cash flow, and net profitability
Click here to access the live audio webcast presentation at 10.00 CET today,
call numbers: US +1-480-629-9866, Belgium +32-2290-1608, Netherlands +31-20-794-8504
Mechelen, Belgium; 3 August 2012 – Galapagos NV (Euronext: GLPG) announces its unaudited half year results and maintains guidance for the full year 2012.
“Galapagos delivered strong results in the first half year, both operationally and financially. The Company is well on track in its global collaboration with Abbott to develop and commercialize GLPG0634. Patient recruitment for the Phase 2a dose-range finding study is complete, and we will announce topline results before year end. The Service division continues to deliver excellent growth in external sales and healthy margins in the first half of 2012. Galapagos is moving its own R&D programs forward and executing as planned to meet financial guidance given earlier this year,” said Galapagos CEO, Onno van de Stolpe.
Gerelateerde downloads
Datum laatste update: 01 september 2024